Justin Rushing
Family Medicine · Cullman, ALNPI 1134656556
Payments from drug & device makers
Across 82 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$249
- AbbVie$226
- Novartis$131
- GSK$114
- AstraZeneca$78
- Amgen$73
- plus $492 from 17 others
What the payments were for
- Food & beverage$1,364100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $249 |
| AbbVie | 14 | $226 |
| Novartis | 7 | $131 |
| GSK | 8 | $114 |
| AstraZeneca | 5 | $78 |
| Amgen | 4 | $73 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $53 |
| Amarin Pharma, Inc. | 3 | $50 |
| Bayer | 3 | $48 |
| Merck | 3 | $43 |
| Pfizer | 3 | $42 |
| Lilly USA, LLC | 2 | $26 |
| Sanofi | 1 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Exact Sciences | 1 | $20 |
| Beigene USA, Inc. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Abbott | 1 | $15 |
| Hartmann USA, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$1,364 in reported general payments places this provider in the 60th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 20 | $13,422 |
| EliquisApixaban | 16 | $10,269 |
| Celecoxib | 11 | $1,186 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 72 | $1,170 |
| Pregabalin | 11 | $695 |
| Duloxetine Hcl | 14 | $577 |
| Rosuvastatin Calcium | 35 | $564 |
| Diclofenac Sodium | 19 | $407 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 16 | $356 |
| Losartan Potassium | 24 | $354 |
| Gabapentin | 21 | $345 |
| Famotidine | 14 | $279 |
| Metoprolol Succinate | 22 | $262 |
| Atorvastatin Calcium | 15 | $249 |
| Pantoprazole Sodium | 18 | $247 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $78 | $13,42220 claims |
| PfizerEliquis | $42 | $10,26916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Cullman
- Randall QuinnCullman$5.4M
- Ben BostickCullman$1.5M
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.